$599

ATTD 2025 Key Press Releases (March 21)  

On the third day of ATTD 2025, five cardiometabolic-related news items have been observed from Novo Nordisk, Skye Bioscience, Terns Pharmaceuticals, Allurion Technologies, and Alnylam Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items. 

This content is for Read Less members only.
Register
Already a member? Log in here